OPEN ACCESS
Read now:
Latest Impact Factor: 5.515
The Official Journal of: American Thyroid Association®
No Effect of Levothyroxine and Levothyroxine-induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects
Funan Huang, Antoinette Ajavon-Hartmann, Erya Huang, John Lettieri, Rong Liu, Carol Pena, Matthias Berse
Prevalence and characterization of thyroid hemiagenesis in Japan: The Fukushima Health Management Survey
Satoru Suzuki, Sanae Midorikawa , Takashi Matsuzuka, Toshihiko Fukushima, Yuko Ito, Hiroki Shimura, Hideto Takahashi, Tetsuya Ohira, Akira Ohtsuru, Masafumi Abe, Shinichi Suzuki, Shunichi Yamashita
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
Yasuhiro Ito, Naoyoshi Onoda, Ken-ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada
Defining Radioiodine-refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-refractory Criteria in the SELECT Trial
Naomi Kiyota, Bruce Robinson, Manisha H Shah MD, Ana O. Hoff, Matthew Taylor, Di Li, Corina E. Dutcus, Eun Kyung Lee, Sung-Bae Kim, Makoto Tahara
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.